• 1
    World Health Organization. The World Health Report. Geneva, Switzerland: World Health Organization; 1997.
  • 2
    Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation (2). N Engl J Med 1989; 321: 10921099.
  • 3
    Dan YY, Wai CT, Yeoh KG, Lim SG. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transpl 2006; 12: 736746.
  • 4
    Angelico M, Di Paolo D, Trinito MO, Petrolati A, Araco A, Zazza S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 176181.
  • 5
    Ben-Ari Z, Daudi N, Klein A, Sulkes J, Papo O, Mor E, et al. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation. Am J Gastroenterol 2003; 98: 151159.
    Direct Link:
  • 6
    Yi NJ, Suh KS, Cho JY, Kwon CH, Lee KW, Joh JW, et al. Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2007; 13: 451458.
  • 7
    Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008; 134: 18901899.
  • 8
    Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693699.
  • 9
    Figueras J, Jaurrieta E, Valls C, Benasco C, Rafecas A, Xiol X, et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 1997; 25: 14851489.
  • 10
    Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 13941403.
  • 11
    Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246: 502511.
  • 12
    Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004; 10: 534540.
  • 13
    Schlitt HJ, Neipp M, Weimann A, Oldhafer KJ, Schmoll E, Boeker K, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol 1999; 17: 324321.
  • 14
    Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol 2008; 103: 16631673.
    Direct Link:
  • 15
    Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903910.
  • 16
    Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585589.
  • 17
    Wong DK, Yuen MF, Poon RT, Yuen JC, Fung J, Lai CL. Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J Hepatol 2006; 45: 553559.
  • 18
    Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126: 102110.
  • 19
    Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975; 68: 105112.
  • 20
    Scullard GH, Smith CI, Merigan TC, Robinson WS, Gregory PB. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 1981; 81: 987991.
  • 21
    Dai MS, Lu JJ, Chen YC, Perng CL, Chao TY. Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients. Cancer 2001; 92: 29272932.
  • 22
    Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209220.
  • 23
    Saab S, Dong MH, Joseph TA, Tong MJ. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology 2007; 46: 10491056.
  • 24
    Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int 2008; 28: 2838.
  • 25
    Wong SN, Reddy KR, Keeffe EB, Han SH, Gaglio PJ, Perrillo RP, et al. Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl 2007; 13: 334342.
  • 26
    Kiyici M, Yilmaz M, Akyildiz M, Arikan C, Aydin U, Sigirli D, et al. Association between hepatitis B and hepatocellular carcinoma recurrence in patients undergoing liver transplantation. Transplant Proc 2008; 40: 15111517.
  • 27
    Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Busuttil RW, et al. Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B. Transplant Proc 2007; 39: 32763280.
  • 28
    Wong PY, McPeake JR, Portmann B, Tan KC, Naoumov NV, Williams R. Clinical course and survival after liver transplantation for hepatitis B virus infection complicated by hepatocellular carcinoma. Am J Gastroenterol 1995; 90: 2934.
  • 29
    Marzano A, Lampertico P, Mazzaferro V, Carenzi S, Vigano M, Romito R, et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005; 11: 532538.